Abstracts tagged "juvenile dermatomyositis"

Abstract Number: 399 • 2019 ACR/ARP Annual Meeting
Seasonal and Temporal Analyses of Disease Onset and Diagnosis in Myositis Autoantibody Phenotypes in Juvenile Dermatomyositis (JDM)
Gulnara Mamyrova¹, Min Shi ², Ira N. Targoff ³, Rodolfo V. Curiel ¹, Frederick W. Miller ⁴ and Lisa G. Rider ⁵, ¹George Washington University, School of Medicine and Health Sciences, Washington, DC, ²Biostatistics&Computational Biology Branch, NIEHS, NIH, Research Triangle Park, NC, ³Arthritis Immunology Section, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴NIEHS, NIH, Bethesda, MD, ⁵Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Bethesda, MD
Background/Purpose: Published studies suggest seasonal occurrence of disease onset and disease activity in patients with adult idiopathic inflammatory myopathies (IIM).Our objective was to evaluate seasonal…
Abstract Number: 433 • 2019 ACR/ARP Annual Meeting
Comparison of PROMIS Computerized Adaptive Testing-Administered Item Banks versus Fixed Short Forms in Juvenile Myositis
Ruchi Patel ¹, Valeria Esparza ², Jin-Shei Lai ¹, Elizabeth Gray ¹, Rowland Chang ³, David Cella ³ and Kaveh Ardalan⁴, ¹Northwestern University Feinberg School of Medicine, Chicago, ²University of Illinois-Chicago College of Medicine, Chicago, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Background/Purpose: Compared to healthy children, youth with juvenile myositis (JM) often report poorer health-related quality of life (HRQoL). Legacy HRQoL measures may underestimate the impact…
Abstract Number: 771 • 2019 ACR/ARP Annual Meeting
Von Willebrand Factor Is Localized in the Extravascular Tissue of Patients with Juvenile Scleroderma
Natalia Vasquez-Canizares¹, Beamon Agarwal ², Tamar Rubinstein ³, Dawn Wahezi ⁴ and Morayma Reyes Gil ⁵, ¹Children's Hospital at Montefiore, Bronx, NY, ²GenomeRxUS LLC, Providence, PA, ³Children's Hospital at Montefiore/Albert Einstein College of Medicine, Bronx, NY, ⁴Children’s Hospital at Montefiore, New York, ⁵Montefiore Medical Center/Albert Einstein College of Medicine, Bronx
Background/Purpose: Von Willebrand Factor (VWF) is a glycoprotein synthesized in endothelial cells and megakaryocytes that has an essential role in primary hemostasis. There is increasing…
Abstract Number: 788 • 2019 ACR/ARP Annual Meeting
Type I Interferon Score and Interferon Induced Mediators CXCL10 and Neopterin Are Correlated with Disease Activity in Juvenile Dermatomyositis
Rebecca Nicolai¹, Ivan Caiello ², Rava' Lucilla ³, Silvia Rosina ⁴, Francesco Licciardi ⁵, Luisa Bracci Laudiero ², Angelo Ravelli ⁶, Fabrizio De Benedetti ⁷ and Gian Marco Moneta ², ¹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Lazio, Italy, ²Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, ³Clinical Epidemiology Unit, Ospedale Pediatrico Bambino Gesù, Roma, Italy, Rome, Italy, ⁴Giannina Gaslini Institute, IRCCS Clinica Pediatrica e Reumatologia, Genoa, Italy, Genoa, Italy, ⁵Division of Pediatric Immunology and Rheumatology, Regina Margherita Children Hospital,Turin, Italy, Turin, Italy, ⁶IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy, ⁷Bambino Gesù Children’s Hospital, Rome, Italy
Background/Purpose: Interferons (IFNs) seem to play an important role in the pathogenesis of juvenile dermatomyositis (JDM). Our group previously reported that expression of both type…
Abstract Number: 1751 • 2019 ACR/ARP Annual Meeting
A Systematic Literature Review of Efficacy and Safety of Biologic Agents for the Treatment of Juvenile Dermatomyositis
edoardo marrani¹, Sarah Abu Rumeileh ¹, Francesca Tirelli ², Ilaria Maccora ³ and Gabriele Simonini ⁴, ¹Post graduate School of pediatrics, University of Florence, Firenze, Italy, ²Post Graduate School of Pediatrics, University of Florence, Florence, Italy, Firenze, Italy, ³Post Graduate School of Pediatrics, University of Florence, Florence, Italy, Florence, Toscana, Italy, ⁴Anna Meyer Children's Hospital, Flotence, Italy
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare, chronic autoimmune illness characterized by symmetric, proximal muscle damages and involvement of the skin. While first line treatment…
Abstract Number: 1868 • 2019 ACR/ARP Annual Meeting
Clinical Correlations of Autoantibodies Against Heat Shock Cognate 71 kDa Protein in Patients with Juvenile Dermatomyositis
Rie Karasawa¹, James N. Jarvis ², Toshiko Sato ¹, Megumi Tanaka ¹, Mark Hicar ², Kazuo Yudoh ¹, Terrance O’Hanlon ³, Payam Noroozi-Farhadi ³ and Lisa G. Rider ⁴, ¹Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan, ²University at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, ³NIEHS, NIH, Bethesda, MD, ⁴Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Bethesda, MD
Background/Purpose: Juvenile dermatomyositis (JDM) is an inflammatory myopathy characterized by prominent vascular and perivascular inflammation in affected skeletal muscles. The mechanisms of vessel injury in…
Abstract Number: 1871 • 2019 ACR/ARP Annual Meeting
Myositis-Specific Antibodies and Muscle Histopathology in Juvenile Dermatomyositis: New Insights into the Mechanism of Injury
MaiLan Nguyen¹, Vy Do ¹, Paul Yell ¹, Chanhee Jo ², Jie Liu ², Tracey Wright ³ and Chunyu Cai ¹, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Texas Scottish Rite Hospital for Children, Dallas, TX, ³University of Texas Southwestern, Texas Scottish Rite Hospital for Children, Children's Health, Dallas, TX
Background/Purpose: Myositis-specific antibodies (MSAs) are identified in over half of children with JDM and are associated with distinct clinical phenotypes. MSA subtype, in combination with…
Abstract Number: 1924 • 2019 ACR/ARP Annual Meeting
Assessing Psychosocial Needs in Juvenile Dermatomyositis Patients Across the United Kingdom
Polly Livermore¹ and Lucy Wedderburn ², ¹ICH/UCL, Arlesey, United Kingdom, ²ICH/UCL, London, United Kingdom
Background/Purpose: Juvenile Dermatomyositis (JDM) is a rare, autoimmune inflammatory condition primarily affecting the muscles and skin. With a mean age of onset of 7 years…
Abstract Number: 2106 • 2019 ACR/ARP Annual Meeting
Features of Pneumocystis Jirovecii Pneumonia in Juvenile Idiopathic Inflammatory Myopathy
Sara Sabbagh¹, Jessica Neely ², Jamie Lai ³, Anjali Sura ⁴, Kelly Rouster-Stevens ⁵, Svetlana Lvovich ⁶, Tara McGrath ⁷, Lori Tucker ⁸, Heinrike Schmeling ⁹, Jordan Roberts ¹⁰, Lisa G. Rider ¹¹ and Susan Kim ², ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, ²University of California, San Francisco, San Francisco, CA, ³Department of Pediatrics, University of Colorado School of Medicine, Division of Pediatric Rheumatology, Children’s Hospital Colorado, Aurora, CO, ⁴University of Michigan, Ann Arbor, MI, ⁵Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, ⁶Section of Rheumatology, Department of Pediatrics, St. Christopher's Hospital for Children, Drexel University College of Medicine, Philadelphia, PA, ⁷Division of Rheumatology, Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada, ⁸British Columbia Children’s Hospital, Vancouver, Canada, ⁹Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹⁰Boston Children’s Hospital, Harvard Medical School, Boston, MD, ¹¹Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Bethesda, MD
Background/Purpose: Approximately 6% of adults with idiopathic inflammatory myopathy (IIM) develop Pneumocystis jirovecii pneumonia (PJP), and PJP confers higher mortality in IIM patients compared to…
Abstract Number: 2241 • 2019 ACR/ARP Annual Meeting
Parent Perspectives on Addressing Emotional Health for Youth with Juvenile Myositis: A Qualitative Focus Group Study
Kaveh Ardalan¹, Oluwatosin Adeyemi ², Dawn Wahezi ³, Anne Caliendo ⁴, Megan L. Curran ⁵, Jessica Neely ⁶, Susan Kim ⁶, Colleen Correll ⁷, Emily Brunner ⁸ and Andrea Knight ⁹, ¹Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, ²Children's Hospital of Philadelphia, Philadelphia, ³Children’s Hospital at Montefiore, New York, ⁴Northwestern University Feinberg School of Medicine, Chicago, ⁵University of Colorado, Aurora, CO, ⁶University of California, San Francisco, San Francisco, CA, ⁷University of Minnesota, Minneapolis, ⁸Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, ⁹Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: While juvenile myositis (JM) can negatively affect quality of life, studies of the emotional health needs of youth with JM are limited. We examined…
Abstract Number: 2727 • 2019 ACR/ARP Annual Meeting
Mitochondrial Contribution to Juvenile Dermatomyositis Pathogenesis
Bhargavi Duvvuri¹, Lauren Pachman ², Richard Moore ¹, Gabrielle Morgan ², Marisa Klein-Gitelman ², Megan L. Curran ³, Stephen Doty ⁴ and Christian Lood ¹, ¹University of Washington, Seattle, ²Northwestern University, Chicago, ³University of Colorado, Aurora, CO, ⁴Hospital for Special Surgery, New York
Background/Purpose: Though mainly found intracellularly, we recently observed mitochondrial extrusion upon cell death, contributing to inflammation and organ damage in lupus-prone mice. Of note, mitochondria…
Abstract Number: 1851 • 2018 ACR/ARHP Annual Meeting
Physical Function Trajectories in Children with Juvenile Myositis
Kaveh Ardalan¹, Elizabeth L. Gray², Julia (Jungwha) Lee², Madison L. Wolfe³, Gabrielle A. Morgan⁴ and Lauren M. Pachman⁵, ¹Departments of Pediatrics and Medical Social Sciences, Division of Rheumatology, Northwestern University Feinberg School of Medicine/Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ²Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Creighton University School of Medicine, Omaha, NE, ⁴Cure JM Program of Excellence in Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ⁵Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL
Background/Purpose: Juvenile myositis (JM) is an inflammatory disease that causes muscle weakness, skin rashes, and significant deconditioning. Little is known about long-term resolution of physical…
Abstract Number: 2031 • 2018 ACR/ARHP Annual Meeting
Dysregulated NK Cell PLC
Allison A. Throm¹, Joshua B. Alinger¹, Lauren M. Pachman² and Anthony R. French³, ¹Pediatrics, Washington University St Louis, St Louis, MO, ²Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ³Pediatric Rheumatology, Washington University St Louis, Saint Louis, MO
Background/Purpose: Juvenile dermatomyositis (JDM) is a debilitating pediatric autoimmune disease manifesting with characteristic rash and proximal muscle weakness. We investigated signaling abnormalities in immune cell…
Abstract Number: 2285 • 2018 ACR/ARHP Annual Meeting
Factors Associated with Corticosteroid Discontinuation, Complete Clinical Response and Remission in Patients with Juvenile Dermatomyositis
Takayuki Kishi^1,2, William Warren-Hicks³, Nastaran Bayat¹, Ira Targoff⁴, Terri H Finkel⁵, Ellen Goldmuntz⁶, Michael Henrickson⁷, Bianca Lang⁸, Andrew Mammen⁹, Lauren M. Pachman¹⁰, Murray Passo¹¹, Terrance P. O'Hanlon¹, Frederick W. Miller¹, Michael Ward⁹ and Lisa G. Rider¹, ¹Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ²Department of Pediatrics, Tokyo Women's Medical University, Tokyo, Japan, ³EcoStat, Inc., Mebane, NC, ⁴VA Medical Center, University of Oklahoma Health Sciences Center and Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Department of Pediatrics, Nemours Children's Health System/ Nemours Children's Hospital, Orlando, FL, ⁶NIAID, NIH, Bethesda, MD, ⁷Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Department of Pediatrics, IWK Health Centre and Dalhousie University, Halifax, NS, Canada, ⁹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ¹⁰Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ¹¹Division of Rheumatology PTD, Medical University of South Carolina, Charleston, SC
Background/Purpose: We examined patients in a large juvenile dermatomyositis (JDM) registry for frequency of and factors associated with final corticosteroid discontinuation (Steroid DC), complete clinical…
Abstract Number: 477 • 2018 ACR/ARHP Annual Meeting
Early Treatment with Intravenous Pulse Methylprednisolone or Methotrexate Is Associated with Decreased Medication Requirements at 12 and 24 Months in Patients with Juvenile Dermatomyositis: A Propensity Score Analysis
Takayuki Kishi^1,2, Jesse Wilkerson³, Marjo Smith³, Nastaran Bayat¹, Michael Henrickson⁴, Bianca Lang⁵, Murray Passo⁶, Frederick W. Miller¹, Michael Ward⁷ and Lisa G. Rider¹, ¹Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ²Department of Pediatrics, Tokyo Women's Medical University, Tokyo, Japan, ³Social & Scientific Systems, Inc., Durham, NC, ⁴Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Department of Pediatrics, IWK Health Centre and Dalhousie University, Halifax, NS, Canada, ⁶Division of Rheumatology PTD, Medical University of South Carolina, Charleston, SC, ⁷National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: Daily oral prednisone has been the main therapy in juvenile dermatomyositis (JDM), and combination therapy with methotrexate (MTX) introduced soon after diagnosis has been…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.